IP Library Granted Patent US 8,747,870
Granted Patent B2
US 8,747,870 · App. 13/742,877 · Granted Jun 10, 2014

Polymeric compositions and methods of making and using thereof

Inventors: Kavita Gupta (Salt Lake City, UT); Meredith R. Clark (Bethesda, MD); Patrick F. Kiser (Chicago, IL); Julie I. Jay (Salt Lake City, UT)
Assignee: University of Utah Research Foundation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,747,870
App. No.
13/742,877
Granted
Jun 10, 2014
Kind
B2
Abstract

Described herein are polymeric compositions that comprise at least one polymer residue and at least one crosslinking moiety, wherein the polymer residue is crosslinked by the crosslinking moiety and wherein the crosslinking moiety is formed from a reaction between a boronic acid moiety and a hydroxamic acid moiety. Also, described are methods of making and using such polymeric compositions.

Claims (30)

1. A polymeric gel composition comprising a first polymer comprising at least two boronic acid moieties, and a second polymer comprising at least two hydroxamic acid moieties, wherein the first polymer and the second polymer are reversibly crosslinked by reaction between at least one of the boronic acid moieties and at least one of the hydroxamic acid moieties.

2. The composition of claim 1 , wherein the boronic acid moiety comprises Formula IV:

where J 1-4 are independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, alkoxy, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, aryl, heteroaryl, aldehyde, amino, carboxylic acid, ester, ether, halide, hydroxy, azide, nitro, silyl, sulfo-oxo, and thiol.

3. The composition of claim 1 , wherein the boronic acid moiety comprises a moiety having Formula V:

where each J is independently selected from the group consisting of substituted or unsubstituted alkyl, cycloalkyl, alkoxy, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, aryl, heteroaryl, aldehyde, amino, carboxylic acid, ester, ether, halide, hydroxy, azide, nitro, silyl, sulfo-oxo, and thiol.

4. The composition of claim 1 , wherein the hydroxamic acid moiety comprises Formula VI:

where Q 1-4 are independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, alkoxy, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, aryl, heteroaryl, aldehyde, amino, carboxylic acid, ester, ether, halide, hydroxy, azide, nitro, silyl, sulfo-oxo, and thiol.

5. The composition of claim 1 , wherein the hydroxamic acid moiety comprises a phenylhydroxamic acid moiety having Formula VII:

where each Q is independently selected from the group consisting of substituted or unsubstituted alkyl, cycloalkyl, alkoxy, alkenyl, cycloalkenyl, alkynyl, cycloalkynyl, aryl, heteroaryl, aldehyde, amino, carboxylic acid, ester, ether, halide, hydroxy, azide, nitro, silyl, sulfo-oxo, and thiol.

6. The composition of claim 1 , wherein the hydroxamic acid moiety comprises a phenylhydroxamic acid moiety having Formula VIIIa:

where Q is hydroxy, alkoxy, nitro, amino, or halide.

7. The composition of claim 1 , wherein the arylhydroxamic acid moiety comprises a phenylhydroxamic acid moiety having Formula VIIIb:

where Q is hydroxy, alkoxy, nitro, amino, or halide.

8. A polymeric gel composition prepared by contacting a first polymer comprising one or more hydroxamic acid moieties and a second polymer comprising one or more boronic acid moieties under conditions where the hydroxamic acid and boronic acid moieties undergo a reaction to provide a boronate ester.

9. A pharmaceutical composition comprising a bioactive agent and the polymeric gel composition of claim 1 .

10. The pharmaceutical composition of claim 9 , wherein the bioactive compound comprises a growth factor, an anti-inflammatory agent, an anti-cancer agent, an analgesic, an anti-infection agent, an anti-cell attachment agent, an anti-viral agent, a hormone, an antibody, or a therapeutic protein.

11. The pharmaceutical composition of claim 9 , wherein the bioactive agent comprises a microbicide, a spermicide, an anti-inflammatory agent, or mixture thereof.

12. The composition of claim 1 , wherein the composition is contained in or coated on a vaginal device.

13. The composition of claim 12 , wherein vaginal device comprises a vaginal tampon, vaginal ring, vaginal strip, vaginal capsule, vaginal tablet, vaginal pessary, vaginal cup, vaginal film, or vaginal sponge.

14. The composition of claim 1 , wherein the composition is applied to vaginal mucosa in the form of a cream, lotion, or foam.

15. The composition of claim 1 , wherein the boronic acid moiety is an arylboronic acid moiety.

16. The composition of claim 1 , wherein the hydroxamic acid moiety is an arylhydroxamic acid.

17. The composition of claim 1 , wherein the hydroxamic acid moiety is a salicylhydroxamic acid.

18. The composition of claim 1 , wherein at least one of the polymers was synthesized by free radical polymerization of phenylboronic acid (PBA) functionalized vinyl monomers or salicylhydroxamic acid (SHA) functionalized vinyl monomers, optionally with co-monomers based upon acrylic acid.

19. The composition of claim 1 , wherein the polymeric gel has a molecular weight of from about 2,000 Da to about 2,000,000 Da.

20. The composition of claim 1 , wherein the boronic acid moiety is an arylboronic acid moiety, wherein the hydroxamic acid moiety is an arylhydroxamic acid, and wherein the polymeric gel has a molecular weight of from about 2,000 Da to about 2,000,000 Da, and wherein the polymeric gel composition comprises a hydrogel network at physiological pH.

21. The composition of claim 1 , wherein the polymeric gel composition comprises a hydrogel network at acidic pH, wherein the hydrogel viscosity increases when exposed to a more basic pH.

22. The composition of claim 21 , wherein the composition is contained in or coated on a vaginal device, or the composition is applied to vaginal mucosa in the form of a cream, lotion, or foam.

23. The composition of claim 21 , further comprising a bioactive agent.

24. The composition of claim 21 , wherein the bioactive agent is selected from microbicides, spermacides, and anti-inflammatory agents.

Assignments (1)
CONFIRMATORY LICENSE Recorded Jan 6, 2017
From: UNIVERSITY OF UTAH
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 041273/0064 →
Continuity (4)
Continuation 12226547
Provisional Application 60793682 · Apr 20, 2006
Provisional Application 60881889 · Jan 23, 2007
Related Publication 20130129797A1 · May 23, 2013